SEATTLE--(BUSINESS WIRE)--Aug. 2, 2017--
Omeros Corporation (NASDAQ: OMER), today announced that the company will
issue its second quarter 2017 financial results for the period ended
June 30, 2017, on Tuesday, August 8, 2017, after the market closes.
Omeros management will host a conference call and webcast that day at
4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial
results.
Conference Call Details
To access the live conference call via phone, please dial (844) 831-4029
from the United States and Canada or (920) 663-6278 internationally. The
participant passcode is 65217569. Please dial in approximately 10
minutes prior to the start of the call. A telephone replay will be
available for one week following the call and may be accessed by dialing
(855) 859-2056 from the United States and Canada or (404) 537-3406
internationally. The replay passcode is 65217569.
To access the live and subsequently archived webcast of the conference
call, go to Omeros’ website at www.omeros.com
and go to “Events” under the Investors section of the website. Please
connect to the website at least 15 minutes prior to the call to allow
for any software download that may be necessary.
About Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering,
developing and commercializing both small-molecule and protein
therapeutics for large-market as well as orphan indications targeting
inflammation, coagulopathies and disorders of the central nervous
system. Part of its proprietary PharmacoSurgery® platform,
the company’s first drug product, OMIDRIA® (phenylephrine and
ketorolac injection) 1% / 0.3%, was broadly launched in the U.S. in
April 2015. OMIDRIA is the first and only FDA-approved drug (1) for use
during cataract surgery or intraocular lens (IOL) replacement to
maintain pupil size by preventing intraoperative miosis (pupil
constriction) and to reduce postoperative ocular pain and (2) that
contains an NSAID for intraocular use. In the European Union, the
European Commission has approved OMIDRIA for use in cataract surgery and
lens replacement procedures to maintain mydriasis (pupil dilation),
prevent miosis (pupil constriction), and to reduce postoperative eye
pain. Omeros has multiple Phase 3 and Phase 2 clinical-stage development
programs focused on: complement-associated thrombotic microangiopathies;
complement-mediated glomerulonephropathies; Huntington’s disease and
cognitive impairment; and addictive and compulsive disorders. In
addition, Omeros has a proprietary G protein-coupled receptor (GPCR)
platform and controls 54 new GPCR drug targets and corresponding
compounds, a number of which are in preclinical development. The company
also exclusively possesses a novel antibody-generating platform.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170802005486/en/
Source: Omeros Corporation
Cook Williams Communications, Inc.
Jennifer Cook Williams
Investor
and Media Relations
360.668.3701
